13F Holdings
中文EN

AEMD AETHLON MEDICAL INC

Pharmaceutical Preparations · Nasdaq · SEC CIK 882291 · Fiscal year ends 03/31

Financial factors as of 2026-09-30 (2027Q2), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY28.3%
TTM EPS YoY137.1%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-136.8%
ROA-110.1%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets17.4%
Debt / equity0.00x
Current ratio5.37x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.90x
Accruals ratio-11.1%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20262026-03-31FY20252025-03-31FY20242024-03-31FY20232023-03-31FY20222022-03-31
Income statement
Revenue——$0$574,245$294,165
R&D expense$1.91M$2.21M$2.52M$2.75M$2.34M
SG&A expense$2.70M$3.24M$3.90M$4.48M$3.46M
Operating income-$7.29M-$9.34M-$12.64M-$11.90M-$10.42M
Interest expense$14,372$10,109———
Pretax income-$7.15M-$13.39M———
Income tax$0$0$0$0$0
Net income-$7.15M-$13.39M-$12.21M-$12.03M-$10.42M
EBITDA-$6.97M-$9.00M-$12.28M-$11.66M-$10.30M
EPS (basic)-10.61-85.77-38.87-5.86-0.71
EPS (diluted)-10.61-85.77-38.87-5.86-0.71
Weighted avg. shares (diluted)673,945156,085314,0972.05M14.76M
Balance sheet
Cash & equivalents$5.03M$5.60M$5.53M$14.62M$17.16M
Receivables———$0$127,965
Current assets$5.57M$5.95M$6.23M$15.09M$18.16M
PP&E, net$356,822$676,220$1.02M$1.14M$441,238
Intangibles$0$550$1,100$1,650$2,200
Total assets$6.33M$7.36M$8.25M$17.51M$19.42M
Current liabilities$1.45M$1.90M$1.83M$1.51M$1.82M
Total liabilities$1.45M$2.24M$2.48M$2.44M$2.43M
Shareholders' equity$4.89M$5.12M$5.77M$15.06M$16.99M
Shares outstanding314,100201,074328,7282.30M15.42M
Cash flow statement
Operating cash flow-$7.00M-$7.65M-$10.13M-$10.51M-$9.77M
Capital expenditure$3,704$0$250,867$943,109$349,193
Free cash flow-$7.00M-$7.65M-$10.38M-$11.45M-$10.12M
Investing cash flow-$3,704$0-$250,867-$943,109-$349,193
Financing cash flow$6.52M$7.73M$1.29M$8.91M$17.37M
Depreciation & amortization$323,653$339,559$359,057$240,892$123,685
Stock-based compensation$278,547$415,234$1.22M$1.05M$750,621

Free plan shows the latest 5 periods; Pro shows all 16 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.